Drugs

, Volume 21, Issue 3, pp 220–225 | Cite as

The Risks of Asymptomatic Hyperuricaemia and the Use of Uricosuric Diuretics

  • Michael W. Johnson
  • William E. Mitch
Review Articles

Summary

Introduction of new uricosuric diuretics will be accompanied by the unknown risk factors associated with the use of any new drug, as demonstrated by reports of hepatic toxicity associated with ticrynafen. In addition to unexpected reactions, there are potential risks related to induction of uricosuria, which are serious and have been reported to occur. More importantly, the risk of developing clinical gout or coronary heart disease due to mild asymptomatic hyperuricaemia appears minimal, so indications for the use of uricosuric diuretics are limited. If a uricosuric diuretic is thought necessary (and is available), it would seem prudent to measure the daily excretion rate of uric acid to identify those patients with hyperuricaemia related to overproduction of uric acid. A uricosuric diuretic should be avoided in those patients, as well as in patients with uric acid stones, and possibly in those with calcium stones. A uricosuric diuretic might be useful for patients with hypertension who also have hyperuricaemia due to a low excretion of uric acid.

Keywords

Uric Acid Gout Serum Uric Acid Kidney Stone Hyperuricemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barlow, K.A. and Beilin, L.J.: Renal disease in primary gout. Quarterly Journal of Medicine 37: 79–96 (1968).PubMedGoogle Scholar
  2. Bennett, W.M.; Vantee, B.E.; Cohen, L.H.; Norby, L.H.; Champion, C. and Spargo, B.: Acute renal failure from Ticrynafen. New England Journal of Medicine 301: 1179–1180 (1980).Google Scholar
  3. Berger, L. and Yu, T.: Renal function in gout. IV: An analysis of 524 gouty subjects including long-term follow-up studies. American Journal of Medicine 59: 605–613 (1975).PubMedCrossRefGoogle Scholar
  4. Boss, G.R. and Seegmiller, J.E.: Hyperuricemia and gout: Classifícation, complications and management. New England Journal of Medicine 300: 1459–1468 (1979).PubMedCrossRefGoogle Scholar
  5. Coe, F.L.: Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Annals of Internal Medicine 87: 404–410 (1977).PubMedGoogle Scholar
  6. Coe, F.L.; Strauss, A.L.; Tembe, V. and LeDun, S.: Uric acid saturation in calcium nephrolithiasis. Kidney International 17: 662–668 (1980).PubMedCrossRefGoogle Scholar
  7. Fanelli, G.M., Jr; Bohn, D.L.; Scriabine, A. and Beyer, K.H.: Saluretic and uricosuric effects of (6, 7-dichloro-2-methyl-loxo-2-phenyl-5-indanyloxy) acetic acid (MK-196) in the chimpanzee. Journal of Pharmacology and Experimental Therapeutics 200: 402–412 (1977).PubMedGoogle Scholar
  8. Fanelli, G.M., Jr; Watson, L.S.; Bohn, D.L. and Russo, H.F.: Diuretic and uricosuric activity of 6, 7-dichloro-2, 3-dihydro-5-(2-thienyl-carbonyl) benzofuran-2-carboxylic acid and stereoisomers in chimpanzee, dog and rat. Journal of Pharmacology and Experimental Therapeutics 212: 190–197 (1980).PubMedGoogle Scholar
  9. Fessel, W.J.: Renal outcomes of gout and hyperuricemia. American Journal of Medicine 67: 74 (1979).PubMedCrossRefGoogle Scholar
  10. Fessel, W.J.: High uric acid as an indicator of cardiovascular disease: Independence from obesity. American Journal of Medicine 68: 401–404 (1980).PubMedCrossRefGoogle Scholar
  11. Fessel, W.J.; Siegelaub, A. and Johnson, E.S.: Correlates and consequences of asymptomatic hyperuricemia. Archives of Internal Medicine 132: 44 (1973).PubMedCrossRefGoogle Scholar
  12. Frohlich, E.D.: Ticrynafen: A new thiazide-like but uricosuric antihypertensive diuretic. New England Journal of Medicine 301: 1378–1382 (1979).PubMedCrossRefGoogle Scholar
  13. Gillies, A.H.B. and Morgan, T.O.: A double blind comparison of the effects of hydrochlorothiazide and tienylic acid (a diuretic with uricosuric properties) in hypertension. British Journal of Clinical Pharmacology 6: 357–362 (1978).PubMedCrossRefGoogle Scholar
  14. Hall, A.P.: Correlations among hyperuricemia, hypercholesterolemia, coronary disease and hypertension. Arthritis and Rheumatism 8: 846–852 (1965).PubMedCrossRefGoogle Scholar
  15. Klein, R.; Klein, B.E.; Cornoni, J.C.; Maready, J.; Cassel, J.C. and Tyroles, H.A.: Serum uric acid: Its relationship to coronary heart disease, risk factors, and cardiovascular disease, Evans County, Georgia. Archives of Internal Medicine 132: 401–410 (1973).PubMedCrossRefGoogle Scholar
  16. McLain, D.A.; Garriga, F.J. and Kantor, O.S.: Adverse reactions associated with ticrynafen use. Journal of the American Medical Association 243: 762–764 (1980).CrossRefGoogle Scholar
  17. Myers, A.R.; Epstein, F.H.; Doge, H.J. and Mikkelsen, W.M.: The relationship of serum uric acid to risk factors in coronary heart disease. American Journal of Medicine 45: 520–528 (1968).PubMedCrossRefGoogle Scholar
  18. Nemati, M.; Kyle, M.C. and Freis. E.D.: Clinical study of ticrynafen, a new diuretic antihypertensive and uricosuric agent. Journal of the American Medical Association 237: 652–657 (1977).PubMedCrossRefGoogle Scholar
  19. Paddack, G.L.; Wahl, R.C.; Holman, R.E.; Schorr, W.J. and Lacher, J.W.: Acute renal failure associated with ticrynafen. Journal of the American Medical Association 243: 764–765 (1980).PubMedCrossRefGoogle Scholar
  20. Paulus, H.E.; Coutts, A.; Calabro, J.J. and Klinenberg, J.R.: Clinical signifícance of hyperuricemia in routinely screened hospitalized men. Journal of the American Medical Association 211: 277–281 (1970).PubMedCrossRefGoogle Scholar
  21. Reese, O.G., Jr and Steele, T.H.: Renal transport of urate during diuretic-induced hyperuricemia. American Journal of Medicine 60: 973–979 (1976).PubMedCrossRefGoogle Scholar
  22. Rosenfeld, J.B.: Effect of long-term allopurinol administration on serial GFR in normotenisve and hypertensive hyperuricemic subjects; in Sperling et al. (Eds) Purine Metabolism in Man: Biochemistry and Pharmacology of Uric Acid Metabolism, pp.581–596 (Plenum Press, New York 1974).Google Scholar
  23. Sawa, H.; Yamakawa, H.; Renjel, L.E. and Fernandes, M.: Acute renal failure during treatment with ticrynafen. Journal of the American Medical Association 243: 766–767 (1980).PubMedCrossRefGoogle Scholar
  24. Seegmiller, J.E.; Grayzel, A.I.; Laster, L. and Liddle, L.: Uric acid production in gout. Journal of Clinical Investigation 40: 1304 (1961).PubMedCrossRefGoogle Scholar
  25. Smith, L.H.: Gout; in Beeson et al. (Eds) Cecil Textbook of Medicine, 15th Edition, pp.2029-2041 (Saunders, Philadelphia, London, Toronto 1979).Google Scholar
  26. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: Influence of age, diastolic pressure and prior cardiovascular disease; further analysis of side effects. Circulation 45: 991 (1972).CrossRefGoogle Scholar
  27. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension. New England Journal of Medicine 301: 293–297 (1979).CrossRefGoogle Scholar
  28. Yu, T. and Katz, W.A.: Gout and pseudogout; in Katz (Ed) Rheumatic Diseases: Diagnosis and Treatment, p.697 (Lippincott, Philadelphia 1977).Google Scholar
  29. Yu, T.; Berger, L.; Dorph, D. and Smith, H.: Renal function in gout. V. Factors influencing the renal hemodynamics. American Journal of Medicine 67: 766 (1979).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd 1981

Authors and Affiliations

  • Michael W. Johnson
    • 1
  • William E. Mitch
    • 1
  1. 1.Clinical Pharmacology Division, Department of MedicineHarvard Medical School and Brigham and Women’s HospitalBostonUSA

Personalised recommendations